HLA-mismatched stem cell microtransplant prolonged overall survival and promoted immunological reconstitution for multiple myeloma
MST extended PFS and OS, and benefit immune reconstitution in multiple myeloma patients. Therefore, MST is a promising treatment for multiple myeloma, especially those with high-risk cytogenetics.
Authors
- Kai‐Xun Hu
- Anli Xie
- Bo Cai (ORCID: https://orcid.org/0000-0002-9208-4445)
- Wei Guan (ORCID: https://orcid.org/0000-0002-5533-6682)
- Hui‐Sheng Ai
- Yangyang Lei (ORCID: https://orcid.org/0009-0003-9486-7544)
- Yingxin Zhao (ORCID: https://orcid.org/0000-0002-8872-5860)
- Jiaxin Chen (ORCID: https://orcid.org/0000-0003-1506-2223)
- Yi Wang (ORCID: https://orcid.org/0000-0002-2067-5465)
- Xiao Lou
- Jian‐Hui Qiao
- Zhiqing Liu (ORCID: https://orcid.org/0000-0003-0266-6677)
- Chang‐Lin Yu
- Xinrui Chen (ORCID: https://orcid.org/0000-0001-8780-4076)
- Ang Zhang (ORCID: https://orcid.org/0000-0002-1196-8960)
- Yajing Huang (ORCID: https://orcid.org/0000-0001-7876-165X)
- Mei Guo (ORCID: https://orcid.org/0000-0001-6954-8873)
- Fei Peng (ORCID: https://orcid.org/0009-0002-6917-0895)
- Qi‐Yun Sun
Institutions
- Chinese PLA General Hospital (CN)
- China National Center for Biotechnology Development (CN)
- Air Force General Hospital PLA (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-04
- DOI
- https://doi.org/10.3389/fimmu.2025.1509588
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality